Neurotech International Limited announced that following recent Board and management changes, Dr. Alexandra Andrews will transition from her current position as Chief Executive Officer (CEO) to a new position of Chief Operating Officer (COO), effective immediately. Alex will continue with the Company in her new capacity of Chief Operating Officer, where she will be providing key scientific, strategic and management input into Neurotech's manufacturing, intellectual property, pre-clinical research and clinical trial development moving forward.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.074 AUD | +1.37% | -1.33% | +7.25% |
04-17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
04-17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
1st Jan change | Capi. | |
---|---|---|
+7.25% | 50.12M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer